INTRODUCTION
Collectively, the advantages associated with microfluidic technologies and microtitre plate automation may enable advancements in biotechnology associated with improved mimics of in vivo processes. For example, the ability to integrate a flow-based and multicellular system with already available microtitre plate technology will enable the properties of absorption, distribution, metabolism, excretion, and toxicity (ADMET) of drug candidates to be analyzed during drug research on a more realistic platform. 1e3 The Food and Drug Administration's Center for Drug Evaluation and Research has reported that it requires anywhere from 0.8 to 1.7 billion dollars for one drug candidate to reach the clinical trial phase, 4 or phase III, of the drugapproval process. It was also determined that 92% of drug candidates that enter into phase I fail before reaching the market due to issues related to the properties of ADMET. Many aspects of the drugdiscovery process, including the mechanism of action of certain drugs, solubility of the drug candidate, and toxicity studies involving the candidate, could be examined in a multicellular system that involves actual blood flow before the drug candidate enters into the clinical trial phase of development. This would allow researchers to discover any unforeseen complications earlier in the drug development stage, thereby reducing the number of drugs that reach clinical trials only to fail and add to the cost associated with testing drug candidates that subsequently fail.
Current techniques for drug development using microtitre plate technology have the advantage of Keywords: microfluidic, microtitre plate, vasodilation, adenosine triphosphate, nitric oxide, ADMET incorporating commercial automation capabilities for HTS. Complex biological sample preparation, introduction of various sample volumes simultaneously, and integrating various instrumentation for sample separation, identification, and quantification are various tasks that can be performed with automated instruments. Due to the acceptance of a standard dimension for the microtitre plate, numerous instruments have been developed on this scale leading to various advancements in the automation and detection methods for this technology.
Although automation of microtitre plate technology can reduce the time required to perform redundant analyses, there are limitations to such systems when applied to drug discovery. For example, current microtitre plate technology results in a static system that is unable to mimic the flowbased vascular system observed in vivo. Processes such as absorption, metabolism, and excretion of drugs within a biological system cannot be accurately examined without incorporating a mimic of blood flow. This is due to certain events being stimulated in vivo by flow-based shear. Also, the current plate design limits the ability to incorporate both adherent and nonadherent cells such as those found within the vascular system (endothelial cells, white blood cells, RBCs, and platelets). This limits the ability to realistically mimic and monitor the toxicity of a drug candidate on a particular cell type of interest while simultaneously monitoring the effect on nontargeted cell types. The current microtitre plate platform is also unable to overcome the complications associated with matrix interferences that are inherent with a complex biological sample such as blood.
Exploiting the benefits of soft lithography techniques and the rapid replica molding associated with poly(dimethylsiloxane) (PDMS), the multidimensional microfluidic array presented here is fabricated in a relatively short period of time. Also, the ability to prepare numerous replica molds from a single master wafer reduces the overall cost per device. In 1998, Duffy et al. 5 published their research demonstrating the ability to fabricate microscale total analysis systems using PDMS. This flow-based system allows for optical transparency, permeability to gases, and provides a nontoxic environment for cell growth. 6 Various manipulations such as pneumatic valving, 7 sample injection techniques, 8 and sample separation 9 are all possible using PDMS-based devices. Moreover, the microscale dimensions of the channels of these microfluidic devices approximate resistance vessels in vivo, allowing for PDMS-based devices to provide a more realistic mimic of an in vivo environment, while including the necessary sample preparation techniques on-chip.
The aforementioned sample-handling features of microfluidic devices can be seamlessly incorporated to the current dimensions of the 96-well plate. As illustrated in Figure 1 , fluid samples can flow into each individual well from sample inlets introduced at the top and bottom of the device. Samples are then directed under each well through channels that are terminated at a waste port adjacent to each column of wells. Immobilization of various cell lines and molecular probes in the wells would take advantage of the automation techniques already in place for 96-well plates, while simultaneously enabling the introduction of flow into the system. By integrating the microfluidic channels and keeping the 
EXPERIMENTAL

Construction of the Microfluidic Array
The microfluidic array is composed of two individual PDMS layers, irreversibly thermocured around a polycarbonate membrane. Blood components are hydrodynamically pumped through the bottom layer within microfluidic channels that are 200-mm wide by 100-mm depth. The top layer comprises an array of 18 wells, each 1/8 in. in diameter, that are separated from the channels by a polycarbonate membrane having pores that are 1 mm in diameter. Samples and standards are pumped at a rate of 1.0 mL/min through the underlying channels for approximately 15 min, allowing the metabolites of interest (e.g., adenosine triphosphate (ATP)) derived from the RBCs in the flowing solution to interact with either cultured endothelial cells (iloprost studies) or a fluorescence probe (metabolite studies) immobilized within each well.
Measurement of Fluorescence Intensity
After capturing the fluorescence images of the array, the pixel intensities were measured for each individual well and correlated to the particular analyte of interest. When determining the effect of iloprost on the RBCs, the fluorescence observed in each well is a result of the intracellular nitric oxide (NO) produced by the cultured bovine pulmonary artery endothelial cells (bPAECs). These cells are immobilized within each well and loaded with 4-amino-5-methylamino-2 9 ,7 9difluorofluorescein diacetate (DAF-FMDA), an intracellular fluorescence probe for NO. The fluorescence intensities were performed with an Olympus IX71 inverted fluorescence microscope using a mercury-arc lamp source; the excitation and emission filtering used a 4 9 ,6-diamidino-2-phenylindole filter cube with excitation and emission wavelengths of 372 and 456 nm, respectively.
To analyze the RBC sample for intracellular nicotinamide adenine dinucleotide phosphate (NADPH) concentrations, an important metabolite in the maintenance of the antioxidant system of the RBC, the wells are filled with a resazurin reaction mixture that becomes fluorescent once reduced in the presence of NADPH. The entire microfluidic array can be imaged in a single snapshot by taking advantage of the low-magnification capabilities of the Olympus MVX fluorescence stereomicroscope. The MVX microscope uses a mercury-arc lamp fitted with a resorufin filter cube with excitation and emission wavelengths of 577 and 620 nm, respectively.
RESULTS AND DISCUSSION
Drug Efficacy and Mechanisms of Action
Recent advancements in drug discovery have shifted to a more mechanistic approach. The development of a device that includes multiple cell types in a single channel, coupled with the fluid-flow forces that are found within the circulation, results in a tool that more closely mimics cell-to-cell communication that may exist in the bloodstream. For instance, overcoming hypertension through vasodilation (resulting from the communication between multiple cell types) can now be investigated more closely using an in vitro platform.
The RBC has been implicated as a determinant in hypertension, a complication associated with various diseases including diabetes, cystic fibrosis, and cardiovascular disease. In this construct, as shown in Figure 2 , a release of ATP Figure 2 . Signal-transduction pathway of iloprost-stimulated vasodilation resulting from RBC-derived ATP release and endotheliumderived NO production.
occurs when RBCs are subjected to stimuli such as mechanical deformation 10 or pharmaceutical agents such as iloprost. 11 The released ATP can migrate to the endothelial cell wall lining the blood vessel, resulting in the activation of the purinergic (P 2Y ) receptor found on the membrane of the endothelial cell. Upon activation of the P 2Y receptor, and in the presence of calcium-dependent calmodulin (Ca 2þ -CaM), nitric oxide synthase (NOS) will convert L-arginine to L-citrulline with the production of NO as a byproduct, ultimately resulting in smooth muscle relaxation and vasodilation.
Our group and others have shown that RBCs from diabetic patients release less ATP compared with RBCs from healthy, nondiabetic controls, when these cells are subjected to mechanical deformation. 12 This is thought to be due, in part, to a reduction in the ability of the cells to fight off oxidant insults, resulting in decreased membrane flexibility when subjected to oxidant stressors. A decrease in glucose-6phosphate dehydrogenase (G6PD) activity results in abnormally lowered levels of the nonenzymatic antioxidant, glutathione (GSH). 13 With a stiffened cellular membrane, the amount of deformation-induced ATP release from the RBCs of diabetic patients is significantly decreased, which may lead to insufficient endothelium-derived NO. This decrease in NO is thought to result in reduced vasodilation and, ultimately, increased hypertension. The ability to monitor cellular processes involving RBCs and other cells (such as the endothelium) will enable the microfluidic array to be used as a clinical diagnostic tool that mimics the in vivo system.
To demonstrate the potential of such a multicellular device to mimic in vivo stimulation of NO by RBC-derived ATP, RBCs were incubated in the presence and absence of iloprost. Iloprost is a therapeutic agent that is thought to induce vasodilation by increasing the amount of NO produced by endothelial cells, 11 which is known to induce smooth muscle relaxation. 14e16 However, it has also been shown that this drug increases the ATP release from RBCs incubated with 1 mM of iloprost for 15 min compared with RBCs in the absence of iloprost. 17 This increase in RBCderived ATP resulted in a 39% increase in the intracellular fluorescence due to the NO produced within the immobilized bPAECs.
Our group has previously examined the necessity of a flow system as it applies to drug efficacy and mechanisms of action; specifically, we have determined the effect of flow on ATP release from RBCs either incubated with pentoxyfilline (Trental) or iloprost. 18 It was determined that the ability of Trental to increase the ATP release from an RBC sample was dependent on the RBC being subjected to flow-induced deformation. In the absence of flow, it was established that Trental did not significantly increase the concentration of ATP released from the RBCs. Therefore, only by monitoring this drug in a flow system could the possible mechanism of action (ATP release) be determined. Furthermore, unpublished results in our group have shown that hydroxyurea, a current treatment for patients with sickle cell disease, 19, 20 also behaves in the same manner, requiring mechanical deformation of the RBC to substantially increase the release of ATP from the RBC.
Personalized Medicine
The ability to use the microfluidic device described here for personalized medicine may lead to improvements in the manner by which drugs are administered to patients. For example, it is anticipated that the microfluidic device shown in Figure 1 may lead to higher success rates of prescribing the right drug for the right patient on the first attempt. Specifically, to prescribe the most effective drug and at an effective dosage, the microfluidic array will allow clinicians to actually monitor the effect on various cell types even before the drug is administered to the patient. For example, this device has been used by our group to determine the concentration of NADPH found within a single RBC sample. This quantitative determination of NADPH, which is a major determinant in the antioxidant status of the cell and is a required metabolite for the reduction of the disulfide form of glutathione (GSSG) to produce GSH (Fig. 3) , is performed in a single step.
A single fluorescence image ( Fig. 4) can be used to simultaneously provide the information necessary to construct a standard calibration curve and quantify the concentration of NADPH contained in a single RBC sample. The microfluidic array used here significantly reduces the time required to make multiple measurements compared with a single measurement detection method. Sample preparation and fabrication of the microfluidic array aside, the actual time required for the entire analysis including the incubation required for the NADPH in solution to react with the fluorescent probe immobilized within each well, is approximately 20 min. This analysis will allow further insight into the cause for a reduced antioxidant status of the RBC on an individual basis, leading to a more specific diagnosis and possibly, an improved method of treatment.
CONCLUSIONS
Most, if not all, in vitro methods involving drug discovery do not incorporate the flow of blood found in vivo. By integrating flow into a HT and automated platform, drug efficacy that is dependent on shear-induced deformation (such as Trental) can now be accurately analyzed using a controlled in vitro platform. As outlined in Table 1 , the combination of features found in microfluidic technologies and microtitre-based measurements are used with the microfluidic array that is described in this work. Many of the advantages of microfluidic devices are associated with the ability to integrate a more lab-on-a-chip approach onto a single device such as the ability to perform on-chip cell culture, sample injection and separation, and incorporate gaseous interfaces and valving techniques. The automation and various technologies already available for microtitre plates will allow this microfluidic array to handle simultaneous and variable sample volumes all by maintaining the currently accepted dimensions of microtitre plates. The microfluidic array holds great possibilities for HT and automated clinical testing and research by combining the advantages listed for each system. 
